» Articles » PMID: 29649974

Delayed and Repeated Intranasal Delivery of Bone Marrow Stromal Cells Increases Regeneration and Functional Recovery After Ischemic Stroke in Mice

Overview
Journal BMC Neurosci
Publisher Biomed Central
Specialty Neurology
Date 2018 Apr 14
PMID 29649974
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Stroke is a leading cause of death and disability worldwide, yet there are limited treatments available. Intranasal administration is a novel non-invasive strategy to deliver cell therapy into the brain. Cells delivered via the intranasal route can migrate from the nasal mucosa to the ischemic infarct and show acute neuroprotection as well as functional benefits. However, there is little information about the regenerative effects of this transplantation method in the delayed phase of stroke. We hypothesized that repeated intranasal deliveries of bone marrow stromal cells (BMSCs) would be feasible and could enhance delayed neurovascular repair and functional recovery after ischemic stroke.

Results: Reverse transcription polymerase chain reaction and immunocytochemistry were performed to analyze the expression of regenerative factors including SDF-1α, CXCR4, VEGF and FAK in BMSCs. Ischemic stroke targeting the somatosensory cortex was induced in adult C57BL/6 mice by permanently occluding the right middle cerebral artery and temporarily occluding both common carotid arteries. Hypoxic preconditioned (HP) BMSCs (HP-BMSCs) with increased expression of surviving factors HIF-1α and Bcl-xl (1 × 10 cells/100 μl per mouse) or cell media were administered intranasally at 3, 4, 5, and 6 days after stroke. Mice received daily BrdU (50 mg/kg) injections until sacrifice. BMSCs were prelabeled with Hoechst 33342 and detected within the peri-infarct area 6 and 24 h after transplantation. In immunohistochemical staining, significant increases in NeuN/BrdU and Glut-1/BrdU double positive cells were seen in stroke mice received HP-BMSCs compared to those received regular BMSCs. HP-BMSC transplantation significantly increased local cerebral blood flow and improved performance in the adhesive removal test.

Conclusions: This study suggests that delayed and repeated intranasal deliveries of HP-treated BMSCs is an effective treatment to encourage regeneration after stroke.

Citing Articles

In Vivo Bioluminescence Imaging of Tumor Progression in the Lewis Lung Carcinoma Orthotopic Mouse Model: A Comparison Between the Tail Vein Injection and Intranasal Instillation Methods.

Yamada-Hara M, Takahashi N, Byun J, Zeng L, Wang Z, Tanaka A Curr Protoc. 2024; 4(12):e70071.

PMID: 39660610 PMC: 11649249. DOI: 10.1002/cpz1.70071.


Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis.

Shen Z, Tang X, Zhang Y, Jia Y, Guo X, Guo X Stem Cells Transl Med. 2024; 13(9):886-897.

PMID: 39159204 PMC: 11386217. DOI: 10.1093/stcltm/szae040.


Brain repair mechanisms after cell therapy for stroke.

Rust R, Nih L, Liberale L, Yin H, El Amki M, Ong L Brain. 2024; 147(10):3286-3305.

PMID: 38916992 PMC: 11449145. DOI: 10.1093/brain/awae204.


Preconditioning of MSCs for Acute Neurological Conditions: From Cellular to Functional Impact-A Systematic Review.

Serrenho I, Ferreira S, Baltazar G Cells. 2024; 13(10.

PMID: 38786067 PMC: 11119364. DOI: 10.3390/cells13100845.


Therapeutic potential of mesenchymal stem cells for cerebral small vessel disease.

Chen D, Huang J, Su S, Chen Q, Wu B Regen Ther. 2024; 25:377-386.

PMID: 38414558 PMC: 10899004. DOI: 10.1016/j.reth.2023.11.002.


References
1.
Stern M, Lappe D, Bowen P, Chimosky J, Holloway Jr G, KEISER H . Continuous measurement of tissue blood flow by laser-Doppler spectroscopy. Am J Physiol. 1977; 232(4):H441-8. DOI: 10.1152/ajpheart.1977.232.4.H441. View

2.
Onda T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis J . Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. J Cereb Blood Flow Metab. 2007; 28(2):329-40. PMC: 2605394. DOI: 10.1038/sj.jcbfm.9600527. View

3.
Fischer U, Harting M, Jimenez F, Monzon-Posadas W, Xue H, Savitz S . Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2008; 18(5):683-92. PMC: 3190292. DOI: 10.1089/scd.2008.0253. View

4.
van Velthoven C, Sheldon R, Kavelaars A, Derugin N, Vexler Z, Willemen H . Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke. Stroke. 2013; 44(5):1426-32. PMC: 3694433. DOI: 10.1161/STROKEAHA.111.000326. View

5.
Kokaia Z, Thored P, Arvidsson A, Lindvall O . Regulation of stroke-induced neurogenesis in adult brain--recent scientific progress. Cereb Cortex. 2006; 16 Suppl 1:i162-7. DOI: 10.1093/cercor/bhj174. View